Key result
Multiple lipid-lowering, anti-inflammatory, and metabolic therapies carry proven outcome benefits in chronic coronary syndromes.
Why the study?
Do advanced and emerging medical therapeutic strategies targeting dyslipidemia, inflammation, and thrombus formation reduce cardiovascular burden and mortality risk in patients with chronic coronary syndromes?
Do advanced and emerging medical therapeutic strategies targeting dyslipidemia, inflammation, and thrombus formation reduce cardiovascular burden and mortality risk in patients with chronic coronary syndromes?
This narrative review contextualizes established, add-on, and emerging investigational therapies targeting dyslipidemia, inflammation, and thrombosis within the 2024 ESC and 2023 ACC/AHA chronic coronary syndrome guidelines.
Answers are grounded in this paper and cite their sources.
Reinforces guideline-endorsed CCS therapies; leaves novel agents open pending dedicated CVOT confirmation.
Chronic coronary syndromes (CCSs) encompass obstructive and non-obstructive coronary artery disease, including epicardial atherosclerosis, coronary microvascular dysfunction, and coronary vasospasm, which may lead to angina pectoris, myocardial infarction, heart attack, and sudden death. Understanding the pathophysiology of CCS has led to targeted therapeutic approaches aimed at managing dyslipidemia, inflammation, and thrombus formation to reduce cardiovascular burden and mortality risk. This review aimed to explore advanced and emerging therapeutic strategies for the treatment of CCS, including advanced lipid-lowering therapies, Lp(a)-lowering RNA agents, novel anti-inflammatory agents, including interleukin-6 (IL-6)-targeted therapy, Factor XIa-targeted antithrombotic therapy, cholesteryl ester transfer protein inhibitors (CETP), angiopoietin-like protein 3 (ANGPTL3) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), nanoparticle-based targeted therapies, and microbiome-modifying therapies. This review situates each therapeutic agent within the 2024 ESC and 2023 ACC/AHA chronic coronary syndrome guidelines and, because regulatory approval, guideline recommendations, and cardiovascular outcome evidence are distinct concepts, considers each separately: high-intensity statins, ezetimibe, PCSK9 inhibitors, low-dose colchicine, and semaglutide are approved and guideline-recommended for defined populations with outcome-trial support; inclisiran and bempedoic acid are approved and guideline-endorsed as add-on lipid-lowering therapies, although inclisiran's dedicated cardiovascular outcomes trial remains ongoing; and pelacarsen, olpasiran, lepodisiran, zerlasiran, ziltivekimab, and obicetrapib remain investigational, with regulatory approval and guideline recommendations contingent on cardiovascular outcomes trial (CVOT) data. Nanomedicine- and microbiome-based approaches remain preclinical or early-phase and are considered hypothesis-generating. Despite promising advances, long-term safety, optimal patient selection, and cardiovascular outcome benefits remain uncertain. Future research should prioritize outcome-driven trials and personalized therapeutic strategies to address residual cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2026) conducted a review in Chronic coronary syndromes (CCS). Advanced and emerging medical therapies (lipid-lowering, Lp(a)-lowering RNA agents, anti-inflammatory agents, Factor XIa inhibitors, CETP inhibitors, ANGPTL3 inhibitors, GLP-1RAs, nanoparticle and microbiome therapies) was evaluated on Cardiovascular burden and mortality risk. High-intensity statins, ezetimibe, PCSK9 inhibitors, low-dose colchicine, and semaglutide are guideline-recommended with outcome support for CCS, while novel RNA and anti-inflammatory agents await CVOT data.
Synapse has enriched 10 related papers. Consider them for comparative context: